Artificial Kidney - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The artificial kidney market size was valued at USD 2.62 billion in 2025 and estimated to grow from USD 2.98 billion in 2026 to reach USD 5.64 billion by 2031, at a CAGR of 13.62% during the forecast period (2026-2031). This report is Segmented by Device Type (Wearable Artificial Kidney, Implantable Artificial Kidney, and More), Technology (Hemodialysis-Based Devices, Peritoneal Dialysis-Based Devices, and More), End User (Hospitals, Specialty Clinics, Home-Care Settings, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Artificial Kidney Market Trends and Insights

Rising CKD & ESRD Prevalence

Worldwide chronic kidney disease cases reached 673 million in 2024, with global mortality climbing to 18.29 per 100,000 population. Diabetes-linked CKD deaths dominate these figures, driving sustained demand for artificial kidney market solutions focused on aging patients. Medicare spent USD 29 billion on hemodialysis in 2024, underscoring the cost pressure on health systems. Asia-Pacific bears the heaviest load, with 450 million people affected and annual therapy costs at USD 23,358 per patient. These epidemiological trends amplify the artificial kidney market’s long-term growth engine and accelerate adoption of portable and implantable alternatives.

Scarcity of Donor Kidneys

Only 21,000 deceased donor kidney transplants occurred in the United States during 2024, leaving more than 92,000 patients on waiting lists. The median transplant waiting time exceeds five years, elevating interest in bio-artificial and xenotransplantation alternatives. FDA clearance for trials using genetically modified pig kidneys in February 2025 signals regulatory momentum that reinforces the artificial kidney market. Global therapy coverage gaps, where only 74% of countries can treat more than half of eligible patients, further widen opportunity for scalable artificial kidney solutions.

High Product & Procedure Costs

Private insurers paid USD 10,149 per month for outpatient dialysis in 2024, compared with Medicare’s USD 3,364, revealing significant affordability gaps. Labor shortages and rising material costs threaten rural clinic viability. China may lose USD 558 billion over the coming decade in kidney care expenses. High R&D investment in biocompatible materials and lengthy clinical trials push selling prices higher, limiting early uptake of premium devices in the artificial kidney market.

Other drivers and restraints analyzed in the detailed report include:

• Shift to Home & Ambulatory Dialysis
• AI-Enabled Personalized Dialysis Dosing
• Device Biocompatibility & Clotting Risks

Segment Analysis

Bio-artificial kidneys post a 21.58% CAGR through 2031, the fastest expansion within the artificial kidney market. The KidneyX-backed implant from the University of California San Francisco integrates silicon nanopore filters with living renal tubule cells, promising complete autonomy from external power sources. Portable hemodialysis units, such as Quanta’s SC+, maintain 41.98% revenue leadership in 2025 after securing FDA clearance.

Implantable designs under investigation at UCLA Health employ nanocellulose ultrafiltration and electrodeionization to eliminate dialysate. The artificial kidney market size for implantables is projected to expand rapidly once pivotal trials demonstrate safety and durability. Wearable concepts, including the belt-worn 11-pound system advanced through FDA expedited pathways, aim to restore patient mobility during therapy.

Complete Report Scope:

• By Device Type
  • Wearable Artificial Kidney
  • Implantable Artificial Kidney
  • Portable Hemodialysis System
  • Bio-artificial (Cell-seeded) Kidney
• By Technology
  • Hemodialysis-based Devices
  • Peritoneal Dialysis-based Devices
  • Sorbent-based Regeneration Tech
  • Nano-electrokinetic ICP Devices
• By End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home-care Settings
  • Other End Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America holds 39.55% of artificial kidney market share in 2025, supported by robust reimbursement frameworks and multiple FDA breakthrough designations for wearable systems. The ESRD Prospective Payment System set a USD 273.82 per-treatment rate that sustains provider economics. Despite this strength, supply chain shortages of hemodialysis bloodlines in 2025 exposed infrastructure fragility. FTC scrutiny of noncompete clauses may boost talent mobility and device innovation.

Asia-Pacific leads growth at 18.05% CAGR through 2031 due to aging populations and rising diabetes prevalence. Chinese approvals for renal denervation and transdermal GFR monitoring speed device availability. Japan’s AI-enabled CKD database improves early detection, supporting earlier therapy initiation. Vantive’s USD 1 billion commitment to digital dialysis underscores private-sector confidence in the region.

Europe experiences steady expansion under value-based healthcare mandates. Multinational trials for the Carry Life UF system demonstrate cross-border collaboration on advanced peritoneal dialysis technologies. Policy forums that target home dialysis inequity spur reimbursement reforms, yet variability in provider incentives slows uniform adoption. Harmonized EMA pathways simplify clinical trial administration, benefitting exporters that aim to scale within the artificial kidney market.

List of Companies Covered in this Report:

• Fresenius
• Baxter
• Medtronic
• B. Braun
• DaVita
• Nipro
• Nikkiso Co. Ltd.
• Asahi Kasei
• AWAK Technologies
• Outset Medical
• Quanta Dialysis Technologies
• Xcorporeal Inc.
• Nanodialysis BV
• SB-KAWASUMI Laboratories Inc.
• Medica S.p.A.
• Toray Medical Co. Ltd.
• Cantel Medical
• Biolife Medical
• Blood Purification Technologies Inc.
• Diality Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support